Incorporating Multiple Imputation Into Tanezumab Dose-Response Modeling of WOMAC Pain CFB Across Six Randomized Placebo-Controlled Phase 3 Trials.

CPT Pharmacometrics Syst Pharmacol · 2025 · PMC12439290 · PMID 40566820

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

If the reason for missingness is related to covariates being tested, then SCM results could potentially vary across MI datasets, and borderline significant/non‐significant results could lead to varied selection/non‐selection across the 100 SCM runs.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.